Literature DB >> 8950981

Identification of novel mdm2 binding peptides by phage display.

V Böttger1, A Böttger, S F Howard, S M Picksley, P Chène, C Garcia-Echeverria, H K Hochkeppel, D P Lane.   

Abstract

The oncogene mdm2 and its human homologue hdm2 bind to the tumour suppressor protein p53 and inactivate its function as a transcription factor. This has been implied as a possible mechanism for cancer development in several tumours including human sarcomas. The mdm2-p53 interaction is therefore a much persued target for the development of anti-cancer drugs. In order to find novel high affinity ligands for hdm2 which would interfere with its binding to p53 we screened phage display peptide libraries for mdm2 binding phage. We found a series of 12 and 15mer peptides which interact strongly with hdm2. The peptide sequences show striking homology with the previously established mdm2 binding site on p53, confirming that the peptide defined 18TFSDLW23 region is crucial for the interaction but that contact between the two molecules extends to position L26 on p53. Free synthetic peptides derived from the phage selected sequences proved to be up to 100 times stronger inhibitors of the p53-mdm2 interaction than the p53 derived wt-peptide in several ELISA-assays. This illustrates the potency of phage display libraries in the search for new peptide based lead structures designed to mimic or inhibit therapeutically important protein-protein interactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8950981

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

Review 1.  Chemical genetics: ligand-based discovery of gene function.

Authors:  B R Stockwell
Journal:  Nat Rev Genet       Date:  2000-11       Impact factor: 53.242

2.  Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage.

Authors:  K Webley; J A Bond; C J Jones; J P Blaydes; A Craig; T Hupp; D Wynford-Thomas
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 3.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

4.  Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Authors:  M S Rodriguez; J M Desterro; S Lain; D P Lane; R T Hay
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

5.  A function for the RING finger domain in the allosteric control of MDM2 conformation and activity.

Authors:  Bartosz Wawrzynow; Susanne Pettersson; Alicja Zylicz; Janice Bramham; Erin Worrall; Ted R Hupp; Kathryn L Ball
Journal:  J Biol Chem       Date:  2009-02-02       Impact factor: 5.157

6.  Targeting tumor suppressor networks for cancer therapeutics.

Authors:  Xuning Emily Guo; Bryan Ngo; Aram Sandaldjian Modrek; Wen-Hwa Lee
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

7.  Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.

Authors:  Ehsan Sarafraz-Yazdi; Wilbur B Bowne; Victor Adler; Kelley A Sookraj; Vernon Wu; Vadim Shteyler; Hunaiz Patel; William Oxbury; Paul Brandt-Rauf; Michael E Zenilman; Josef Michl; Matthew R Pincus
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

8.  Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif.

Authors:  Erin G Worrall; Bartosz Wawrzynow; Liam Worrall; Malcolm Walkinshaw; Kathryn L Ball; Ted R Hupp
Journal:  J Chem Biol       Date:  2009-05-16

Review 9.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

10.  Intracellular expression of Peptide fusions for demonstration of protein essentiality in bacteria.

Authors:  R Edward Benson; Elizabeth B Gottlin; Dale J Christensen; Paul T Hamilton
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.